Technology is becoming increasingly intertwined in our daily lives, from entertainment to health care. At Pfizer, we put patients first, which means working to evolve the products, services, and treatments we provide to meet their ever-changing needs. This is especially important for patients and families with rare diseases, as there is no one-size-fits-all approach to care.
Pfizer Rare Disease recently partnered with two leading digital companies to transform already popular technologies to help people living with hemophilia better track different aspects related to their disease. Both were debuted at the National Hemophilia Foundation’s 69th Annual Meeting.
Hemocraft™, a modification of the popular video game Minecraft®, was created in partnership with the Entrepreneurial Game Studio at Drexel University and representatives from the hemophilia community. Educating younger patients to be involved in their own care is important, especially as they become more independent. Hemocraft allows users to embark on an interactive quest to learn the importance of sticking to treatment plans, staying prepared, and understanding how infusions work, and motivates them to proactively integrate treatment into their daily routines.
The HemMobile® Striiv®Wearable, developed in partnership with Striiv, works together with Pfizer’s existing hemophilia mobile app, HemMobile®, to offer people with hemophilia accessible, comprehensive tools to track their activity. This custom, health care–focused wearable wristband includes features such as daily activity level tracking, heart rate measurement, factor supply monitoring, personalized report generation, and detailed hemophilia management logs.
Our focus is to motivate patients to be active in their own health care by creating resources that can integrate into their daily routines. Through technology and gaming, both Hemocraft and the HemMobile Striiv Wearable provide people living with hemophilia increased education and tools to help navigate their disease. These new offerings are just a glimpse into how Pfizer Rare Disease is pioneering a new era for people with hemophilia.